Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 134

1.

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.

Ham J, Costa C, Sano R, Lochmann TL, Sennott EM, Patel NU, Dastur A, Gomez-Caraballo M, Krytska K, Hata AN, Floros KV, Hughes MT, Jakubik CT, Heisey DA, Ferrell JT, Bristol ML, March RJ, Yates C, Hicks MA, Nakajima W, Gowda M, Windle BE, Dozmorov MG, Garnett MJ, McDermott U, Harada H, Taylor SM, Morgan IM, Benes CH, Engelman JA, Mossé YP, Faber AC.

Cancer Cell. 2016 Feb 8;29(2):159-72. doi: 10.1016/j.ccell.2016.01.002.

2.

Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response.

Conery AR, Centore RC, Spillane KL, Follmer NE, Bommi-Reddy A, Hatton C, Bryant BM, Greninger P, Amzallag A, Benes CH, Mertz JA, Sims RJ 3rd.

Cancer Res. 2016 Mar 15;76(6):1313-9. doi: 10.1158/0008-5472.CAN-15-1458. Epub 2016 Jan 12.

PMID:
26759243
3.

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

Michaut M, Chin SF, Majewski I, Severson TM, Bismeijer T, de Koning L, Peeters JK, Schouten PC, Rueda OM, Bosma AJ, Tarrant F, Fan Y, He B, Xue Z, Mittempergher L, Kluin RJ, Heijmans J, Snel M, Pereira B, Schlicker A, Provenzano E, Ali HR, Gaber A, O'Hurley G, Lehn S, Muris JJ, Wesseling J, Kay E, Sammut SJ, Bardwell HA, Barbet AS, Bard F, Lecerf C, O'Connor DP, Vis DJ, Benes CH, McDermott U, Garnett MJ, Simon IM, Jirström K, Dubois T, Linn SC, Gallagher WM, Wessels LF, Caldas C, Bernards R.

Sci Rep. 2016 Jan 5;6:18517. doi: 10.1038/srep18517.

4.

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.

Gill SJ, Travers J, Pshenichnaya I, Kogera FA, Barthorpe S, Mironenko T, Richardson L, Benes CH, Stratton MR, McDermott U, Jackson SP, Garnett MJ.

PLoS One. 2015 Oct 27;10(10):e0140988. doi: 10.1371/journal.pone.0140988. eCollection 2015.

5.

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.

Friedman AA, Amzallag A, Pruteanu-Malinici I, Baniya S, Cooper ZA, Piris A, Hargreaves L, Igras V, Frederick DT, Lawrence DP, Haber DA, Flaherty KT, Wargo JA, Ramaswamy S, Benes CH, Fisher DE.

PLoS One. 2015 Oct 13;10(10):e0140310. doi: 10.1371/journal.pone.0140310. eCollection 2015.

6.

Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase.

Buisson R, Boisvert JL, Benes CH, Zou L.

Mol Cell. 2015 Sep 17;59(6):1011-24. doi: 10.1016/j.molcel.2015.07.029. Epub 2015 Sep 10.

PMID:
26365377
7.

[Impact of climate changes on the incidence of tick-borne encephalitis in the Czech Republic in 1982-2011].

Kříž B, Kott I, Daniel M, Vráblík T, Beneš Č.

Epidemiol Mikrobiol Imunol. 2015 Mar;64(1):24-32. Czech.

PMID:
25872993
8.

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.

Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, Wagner BL, Rideout WM 3rd, Jakubik CT, Ham J, Edelman EJ, Ebi H, Yeo AT, Hata AN, Song Y, Patel NU, March RJ, Tam AT, Milano RJ, Boisvert JL, Hicks MA, Elmiligy S, Malstrom SE, Rivera MN, Harada H, Windle BE, Ramaswamy S, Benes CH, Jacks T, Engelman JA.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1288-96. doi: 10.1073/pnas.1411848112. Epub 2015 Mar 3.

9.

Increasing Residential Proximity of Lyme Borreliosis Cases to High-Risk Habitats: A Retrospective Study in Central Bohemia, the Czech Republic, 1987-2010.

Zeman P, Benes C, Markvart K.

Ecohealth. 2015 Sep;12(3):519-22. doi: 10.1007/s10393-015-1016-5. Epub 2015 Feb 20.

PMID:
25698296
10.

Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers.

Liu Q, Wang M, Kern AM, Khaled S, Han J, Yeap BY, Hong TS, Settleman J, Benes CH, Held KD, Efstathiou JA, Willers H.

Mol Cancer Res. 2015 Apr;13(4):713-20. doi: 10.1158/1541-7786.MCR-14-0570. Epub 2015 Feb 9.

11.

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.

Flynn RL, Cox KE, Jeitany M, Wakimoto H, Bryll AR, Ganem NJ, Bersani F, Pineda JR, Suvà ML, Benes CH, Haber DA, Boussin FD, Zou L.

Science. 2015 Jan 16;347(6219):273-7. doi: 10.1126/science.1257216.

12.

A coding single-nucleotide polymorphism in lysine demethylase KDM4A associates with increased sensitivity to mTOR inhibitors.

Van Rechem C, Black JC, Greninger P, Zhao Y, Donado C, Burrowes PD, Ladd B, Christiani DC, Benes CH, Whetstine JR.

Cancer Discov. 2015 Mar;5(3):245-54. doi: 10.1158/2159-8290.CD-14-1159. Epub 2015 Jan 6.

13.

Lysine demethylase KDM4A associates with translation machinery and regulates protein synthesis.

Van Rechem C, Black JC, Boukhali M, Aryee MJ, Gräslund S, Haas W, Benes CH, Whetstine JR.

Cancer Discov. 2015 Mar;5(3):255-63. doi: 10.1158/2159-8290.CD-14-1326. Epub 2015 Jan 6.

14.

Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer.

Costa C, Ebi H, Martini M, Beausoleil SA, Faber AC, Jakubik CT, Huang A, Wang Y, Nishtala M, Hall B, Rikova K, Zhao J, Hirsch E, Benes CH, Engelman JA.

Cancer Cell. 2015 Jan 12;27(1):97-108. doi: 10.1016/j.ccell.2014.11.007. Epub 2014 Dec 24.

15.

[Pertussis trend in children under one year of age in the Czech Republic in 1997-2013].

Fabiánová K, Šebestová H, Beneš Č, Zavadilová J, Křížová P, Kříž B.

Epidemiol Mikrobiol Imunol. 2014 Nov;63(4):270, 272-4, 276-7. Czech.

PMID:
25523219
16.

The role of game (wild boar and roe deer) in the spread of tick-borne encephalitis in the Czech Republic.

Kriz B, Daniel M, Benes C, Maly M.

Vector Borne Zoonotic Dis. 2014 Nov;14(11):801-7. doi: 10.1089/vbz.2013.1569.

17.

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A, Greninger P, Lee D, Kalsy A, Gomez-Caraballo M, Elamine L, Howe E, Hur W, Lifshits E, Robinson HE, Katayama R, Faber AC, Awad MM, Ramaswamy S, Mino-Kenudson M, Iafrate AJ, Benes CH, Engelman JA.

Science. 2014 Dec 19;346(6216):1480-6. doi: 10.1126/science.1254721. Epub 2014 Nov 13.

18.

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.

Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, D'Adamo D, Cote GM, Flamand Y, Benes CH, Haber DA, Baselga JM, Demetri GD.

BMC Cancer. 2014 Nov 5;14:813. doi: 10.1186/1471-2407-14-813.

19.

Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.

Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R, Benes C, Engelman JA, Bardeesy N.

Clin Cancer Res. 2015 Jan 15;21(2):396-404. doi: 10.1158/1078-0432.CCR-14-1591. Epub 2014 Oct 27.

20.

Drugging MYCN through an allosteric transition in Aurora kinase A.

Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, Simonds EF, Seeger R, Matthay KK, Hertz NT, Eilers M, Shokat KM, Weiss WA.

Cancer Cell. 2014 Sep 8;26(3):414-27. doi: 10.1016/j.ccr.2014.07.015. Epub 2014 Aug 28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk